Investigational therapies for metastatic thyroid carcinoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 6, 2007, Pages 641-646

  Tuttle, R Michael ^a,c   Leboeuf, R ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Novel therapy; Thyroid cancer; Tyrosine kinase inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; AZACITIDINE; B RAF KINASE; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; COMBRETASTATIN A4; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELDANAMYCIN; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; RAPAMYCIN; ROSIGLITAZONE; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VASCULOTROPIN; VATALANIB; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; EPIGENETICS; GENE MUTATION; HUMAN; METASTASIS; PATIENT SELECTION; REVIEW; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

EID: 34447339642     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0055     Document Type: Review

References (32)

1. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-1463.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 1998;83:2638-2648.
3. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-128.
4. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7:229-239.
5. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-2899.
6. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
7. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-156.
8. Milano A, Chiofalo MG, Basile M, et al. New molecular targeted therapies in thyroid cancer. Anticancer Drugs 2006;17:869-879.
9. Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 2002;87:4160-4165.
10. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differenriated thyroid cancer. Thyroid 2006;16:109-142.
11. Sherman SI, Angelos P, Ball DW, et al. NCCN thyroid cancer clinical practice guidelines in oncology v.2.2007. Available at http://www.nccn.org/ professionals/physician_gls/PDF/thyroid.pdf. Accessed May 17, 2007.
12. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets tor solid cancer pharmacotherapy. J Endocrinol 2004; 183:249-256.
13. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
14. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16-20.
15. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 2007;19:18-23.
16. Drosten M, Putzer BM. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006;3:564-574.
17. Shen WT, Chung WY. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid 2005;15:594-599.
18. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007;148:948-953.
19. Braga-Basaria M, Ringel MD. Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 2003;88:1947-1960.
20. Shchemelinin I, Sefc L, Necas E. Protein kinase inhibitors. Folia Biol (Praha) 2006;52:137-148.
21. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362.
22. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 2006;155:495-512.
23. Coelho SM, Vaisman M, Carvalho DP. Tumour re-differentiation effect of rerinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 2005;11:2525-2531.
24. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.
25. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current status and future prospects. Thyroid 2004;14:424-434.
26. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2201-2204.
27. Liu YY, Stokkel MP, Pereira AM, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154:525-531.
28. Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-966; discussion 966-967.
29. Kohlfuerst S, Igerc I, Gallowitsch HJ, et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-posirive metastases? Thyroid 2006;16:1113-1119.
30. Robbins RJ, Hill RH, Wang W, et al. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000;10:177-183.
31. Strumberg D, Voliotis D, Moeller JG, et al. Results of phase 1 pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitot BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-581.
32. Fury MG, Solit DB, Su YB, et al. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007;59:467-475.